Amgevita™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

Listen to the audio transcription of the CMI leaflet.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Rheumatoid arthritis (RA),AMGEVITA is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active RA. This includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate (MTX).,AMGEVITA can be used alone or in combination with MTX.,Juvenile idiopathic arthritis (JIA),Polyarticular juvenile idiopathic arthritis (pJIA),AMGEVITA in combination with MTX is indicated for reducing the signs and symptoms of moderately to severely active pJIA in patients 2 years of age and older who have had an inadequate response to one or more disease modifying anti-rheumatic drugs (DMARDs). AMGEVITA can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate.,Enthesitis-related arthritis (ERA),AMGEVITA is indicated for the treatment of ERA in children, who have had an inadequate response to, or who are intolerant to, conventional therapy.,Psoriatic arthritis (PsA),AMGEVITA is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderately to severely active PsA in adult patients where response to previous DMARDs has been inadequate.,Ankylosing spondylitis (AS),AMGEVITA is indicated for reducing signs and symptoms in patients with active AS.,Crohns disease (CD) in children (equal to or greater than 6 years) and adults,AMGEVITA is indicated for the treatment of moderate to severe CD, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients who have:,had an inadequate response to conventional therapies or,,lost response to or are intolerant of infliximab.,Ulcerative colitis (UC),AMGEVITA is indicated for the treatment of moderate to severe UC in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. Patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time (see section 5.1 Pharmacodynamic properties - Clinical trials).,Psoriasis (Ps) in children and adults,AMGEVITA is indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.,AMGEVITA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,Hidradenitis suppurativa (HS) in adults and adolescents (from 12 years of age),AMGEVITA is indicated for the treatment of active moderate to severe HS (acne inversa) in patients with an inadequate response to conventional systemic HS therapy.,Uveitis,AMGEVITA is indicated for the treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.

Source: ARTG

• Shelf lifetime is 36 Months
• Store at 2 to 8 degrees Celsius
• Do not Freeze; Refrigerate

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, solution
• Subcutaneous
• Liquid, practically free from particles

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 1

Source: ARTG

This medicine is not listed on the Pharmaceutical Benefits Scheme (PBS). Talk to your pharmacist about how much it will cost.

Source: PBS

For the active ingredient: Adalimumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).